Drug Trial Radar · NCT06253715
Shortened Regimen for Drug-susceptible TB in Children
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
860
Planned (sponsor's estimate)
Start
Jan 15, 2025
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Agency for International Development (USAID); Medical Research Council, South Africa; The ELMA Foundation
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 days, up to 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.
Conditions
- Tuberculosis
- Tuberculosis, Pulmonary
- Tuberculosis, Lymph Node
- Mycobacterium Tuberculosis
Interventions
IsoniazidDrug
Once daily weight-based dose
RifampinDrug
Once daily weight-based dose
PyrazinamideDrug
Once daily weight-based dose
EthambutolDrug
Once daily weight-based dose
RifapentineDrug
Once daily weight-based dose
MoxifloxacinDrug
Once daily weight-based dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- TB disease-free survival at 48-weeksTime frame: Measured from study entry through week 48
- Proportion of participants with grade 3 or higher adverse events over 28 weeksTime frame: Measured from study entry through Week 28
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Indian Council of Medical Research - National Institute for Research in Tuberculosis
Chennai, India · Recruiting
Dr. D.Y. Patil Medical College, Hospital and Research Center
Pune, India · Recruiting
Faculty of Medicine, Universitas Padjadjaran
Bandung, Indonesia · Recruiting
Instituto Nacional de Saúde (INS)
Maputo, Mozambique · Recruiting
Africa Health Research Institute (AHRI)
Durban, South Africa · Recruiting
MU-JHU Care Ltd
Kampala, Uganda · Recruiting
University of Zambia, School of Medicine
Lusaka, Zambia · Recruiting
Arthur Davison Children's Hospital
Ndola, Zambia · Recruiting
Harare Health and Research Consortium (HHRC)
Harare, Zimbabwe · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.